NAN August 2017

NORTHAMERICANEWS / August 2017 29 The central common area of Geneva Commons in City of Geneva (Illinois), is about to undergo MAVYRET is an eight-week, pan-genotypic option for patients without cirrhosis and who are new to treatment, who comprise most people living with HCV. MAVYRET is also approved as a treatment for patients with specific treatment challenges, including those (GT1) not cured by prior treatment experience to either a protease inhibitor or NS5A inhibitor (but not both), and in patients with limited treatment options, such as those with severe chronic kidney disease (CKD) or those with genotype 3 chronic HCV. MAVYRET is a pan-genotypic treatment approved for use in patients across all stages of CKD. Glecaprevir (GLE) was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals (NASDAQ: ENTA) for HCV protease inhibitors and regimens that include protease inhibitors. MAVYRET™ (glecaprevir and pibrentasvir) tablets are a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C virus (hep C) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis. What is the most important information to know about MAVYRET? Hepatitis B virus reactivation: Before starting treatment with MAVYRET, a doctor will do blood tests to check for hepatitis B virus infection. If people have ever had hepatitis B virus infection, the hepatitis B virus could become active again during or after treatment of hepatitis C virus with MAVYRET. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure and death. A doctor will monitor people if they are at risk for hepatitis B virus reactivation during treatment and after they stop taking MAVYRET. MAVYRET must not be taken if people: • Have certain liver problems • Are taking the medicines: - atazanavir (Evotaz ® , Reyataz ® ) - rifampin (Rifadin®, Rifamate®, Rifater ® , Rimactane ® ) What should people tell a doctor before taking MAVYRET? If they have ever had hepatitis B virus infection, liver problems other than hep C infection, or any other medical conditions. If they are pregnant or plan to become pregnant, or if they are breastfeeding or plan to breastfeed. It is not known if MAVYRET will harm a person’s unborn baby or pass into breast milk. A doctor should be consulted about the best way to feed a baby if taking MAVYRET. About all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. MAVYRET and other medicines may affect each other. This can cause people to have too much or not enough MAVYRET or other medicines in their body. This may affect the way MAVYRET or other medicines work, or may cause side effects. A new medicine must not be started without telling a doctor. A doctor will provide instruction on whether it is safe to take MAVYRET with other medicines. What are the common side effects of MAVYRET? The most common side effects of MAVYRET are headache and tiredness. These are not all the possible side effects of MAVYRET. A doctor should be notified if there is any side effect that is bothersome or that does not go away. This is the most important information to know about MAVYRET. For more information, people should talk to a doctor or healthcare provider. People are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. If people cannot afford their medication, they should contact www.pparx. org for assistance. For more information about AbbVie, please visit www.abbvie.com (1) Messina JP, Humphreys I., Flaxman A., et.al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1): 77-87 (and supplementary appendix). (2) IMS Health. IMS Dx/LRx. December 2016. (©IMS Health Inc., all rights reserved). www.abbvie.com